Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure-Reference-Cited by-同舟云学术

Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure

Published:2022-01-13 Issue:2 Volume:9 Page:885-893
ISSN:2055-5822
Container-title:ESC Heart Failure
language:en
Short-container-title:ESC Heart Failure

Author:

Usman Muhammad Shariq¹,Khan Muhammad Shahzeb²,Fonarow Gregg C.³,Greene Stephen J.²,Friede Tim⁴⁵,Vaduganathan Muthiah⁶,Filippatos Gerasimos⁷,Coats Andrew J. Stewart⁸⁹,Anker Stefan D.¹⁰,Butler Javed¹

Affiliation:

1. Department of Medicine University of Mississippi Jackson MS USA

2. Division of Cardiology Duke University Medical Center Durham NC USA

3. Division of Cardiology Ronald Reagan UCLA Medical Center Los Angeles CA USA

4. Department of Medical Statistics University Medical Center Göttingen Göttingen Germany

5. DZHK (German Centre for Cardiovascular Research), partner site Göttingen Göttingen Germany

6. Brigham and Women's Hospital Heart & Vascular Center Boston MA USA

7. National and Kapodistrian University of Athens School of Medicine Athens University Hospital Attikon Athens Greece

8. Department of Cardiology IRCCS San Raffaele Pisana Rome Italy

9. University of Warwick Coventry UK

10. Department of Cardiology (CVK); and Berlin Institute of Health Center for Regenerative Therapies (BCRT); DZHK (German Centre for Cardiovascular Research), partner site Berlin Charité—Universitätsmedizin Berlin Berlin Germany

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ehf2.13785

Reference13 articles.

1. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

2. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

3. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

4. Fragility Index in Cardiovascular Randomized Controlled Trials

5. Application of the Reverse Fragility Index to Statistically Nonsignificant Randomized Clinical Trial Results

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes;Diabetes Epidemiology and Management;2023-04

2. Efficacy and safety profile of SGLT2 inhibitors in the elderly: How is the benefit/risk balance?;Diabetes & Metabolism;2023-03

3. Six lessons learned from the use of SGLT2 inhibitors in patients with heart failure;Nature Reviews Cardiology;2022-06-13